Y Intercept Hong Kong Ltd Acquires Shares of 23,945 Alto Neuroscience, Inc. $ANRO

Y Intercept Hong Kong Ltd bought a new position in Alto Neuroscience, Inc. (NYSE:ANRO) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 23,945 shares of the company’s stock, valued at approximately $538,000.

A number of other institutional investors have also recently modified their holdings of the stock. Torren Management LLC purchased a new position in shares of Alto Neuroscience in the 4th quarter worth about $62,000. XTX Topco Ltd increased its stake in Alto Neuroscience by 32.2% during the 4th quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock valued at $371,000 after purchasing an additional 5,078 shares in the last quarter. AlphaCore Capital LLC increased its stake in Alto Neuroscience by 100.0% during the 4th quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $356,000 after purchasing an additional 10,000 shares in the last quarter. Balyasny Asset Management L.P. purchased a new position in Alto Neuroscience in the fourth quarter worth about $198,000. Finally, Armistice Capital LLC raised its holdings in Alto Neuroscience by 0.7% in the third quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock worth $6,577,000 after buying an additional 12,000 shares during the last quarter.

Alto Neuroscience Stock Performance

Shares of ANRO stock opened at $28.10 on Tuesday. The company has a 50 day moving average price of $22.92 and a 200-day moving average price of $20.96. Alto Neuroscience, Inc. has a 52 week low of $2.53 and a 52 week high of $28.44. The firm has a market capitalization of $985.92 million, a PE ratio of -11.61 and a beta of 1.04. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.24). As a group, equities research analysts expect that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current year.

Analyst Ratings Changes

ANRO has been the topic of a number of recent analyst reports. Jefferies Financial Group reiterated a “buy” rating and set a $35.00 price target on shares of Alto Neuroscience in a report on Monday, March 16th. Robert W. Baird decreased their price objective on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Wolfe Research started coverage on Alto Neuroscience in a research report on Friday, May 22nd. They issued an “outperform” rating on the stock. Weiss Ratings upgraded Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. Finally, Wall Street Zen lowered Alto Neuroscience from a “hold” rating to a “strong sell” rating in a report on Sunday, May 17th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $35.25.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.